Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
A recent study published in the European Respiratory Journal showed that domiciliary oxygen therapy (DOXT) had significant benefits for people with pulmonary hypertension, when given alongside their normal treatment.
People with pulmonary hypertension have high blood pressure in the vessels in their lungs, making it harder to get oxygen into the blood and around the body. This leads to difficulty exercising and reduced quality of life. DOXT is a treatment for lung conditions where patients breathe in air with a higher concentration of oxygen than normal.
In this study, 30 people with pulmonary hypertension were randomly separated into two groups. People in the first group were given DOXT through a nasal tube over 5 weeks. They were compared to a second group who were given normal air in the same way.
Neither the patients nor the researchers knew which treatment each group had been given during the study. This was so that the researchers could be sure that any benefit from DOXT was due to the treatment itself, rather than the placebo effect (where people’s symptoms improve because of their belief that a treatment will work).
The researchers found that ability to exercise significantly improved for people who were given DOXT for 5 weeks, compared to people who were given normal air. This was measured by how far the study participants could walk in 6 minutes.
They also found that those who received DOXT had better scores on a questionnaire about physical function compared to the second group.
More studies are needed to better understand the benefits of DOXT, and to confirm the results of this study. But these findings suggest that DOXT could be used alongside existing treatment to help improve the symptoms of pulmonary hypertension.
Read our factsheet on pulmonary hypertension
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79